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Hypoxia is a signature feature of growing tumors. This cellular state creates an inhospitable condition that impedes the growth and
functionofallcellswithintheimmediateandsurroundingtumormicroenvironment.Toadapttohypoxia,cellsactivateautophagy
andundergoametabolicshiftincreasingthecellulardependencyonanaerobicmetabolism.Autophagyupregulationincancercells
liberates nutrients, decreases thebuildup of reactive oxygen species, and aids in theclearance of misfolded proteins. Together, these
features impart a survival advantage for cancer cells in the tumor microenvironment. This observation has led to intense research
eﬀorts focused on developing autophagy-modulating drugs for cancer patient treatment. However, other cells that inﬁltrate the
tumor environment such as immune cells also encounter hypoxia likely resulting in hypoxia-induced autophagy. In light of the
fact that autophagy is crucial for immune cell proliferation as well as their eﬀector functions such as antigen presentation and
T cell-mediated killing of tumor cells, anticancer treatment strategies based on autophagy modulation will need to consider the
impact of autophagy on the immune system.
1.Introduction
In many tumors, cell growth and proliferation exceeds the
development of local vasculature supplying oxygen and
nutrients. As a result, tumors form disorganized angiogenic
vessels that cause the percent of oxygen within the tumor to
range heterogeneously from anoxic (<0.5% O2)a n dh y p o x i c
(0.5–1.5% O2) to normoxic (>1.5% O2)l e v e l s[ 1, 2]. Cancer
cells in close proximity to vasculature contribute to tumor
hypoxia by rapidly utilizing oxygen and nutrients that arrive
at the tumor site. This can result in either chronic or cycling
hypoxia depending on how quickly cancer cells consume
oxygen once new vascular networks are formed [3, 4]. To
circumvent the eﬀects of oxygen deprivation, the transcrip-
tion factor hypoxia inducible factor-1α (HIF-1α) is stabilized
in cells under hypoxia. HIF-1α allows for adaptation to
hypoxia by promoting a metabolic switch from oxidative
phosphorylation to glycolysis and by initiating angiogenesis
[5]. Collectively, the hypoxic and nutrient-depleted tumor
microenvironment impacts the metabolism, survival, and
function of all cells exposed to it.
As a result of hypoxic stress, cells in the tumor microen-
vironment activate autophagy, a cell survival process that
degrades and recycles cellular constituents. Autophagy can
beinducedbyvariousstressorsincludingnutrientstarvation,
growth factor withdrawal, hypoxia, and chemotherapeutic
stress [6–9]. During autophagy, selective or bulk portions
of cytoplasm, including whole organelles, are sequestered in
double-membraned vacuoles called autophagosomes. These
structures fuse with lysosomes to form autophagolysosomes,
the site of degradation for the sequestered cargo. Metabolites
within the autophagolysosome are liberated by vacuolar
permeases, which eﬄux amino acids and other nutrients
from the degradative compartment back into the cytosol
where they are recycled as biosynthetic precursors, or as sub-
strates that are oxidized to support bioenergetics [10]. The
biochemical steps of autophagy initiation, autophagosome
elongation,andrecyclinghavebeenelegantlydocumentedby2 International Journal of Cell Biology
numerous investigators and are the subject of several recent
reviews [11–13]. Here, we focus on the activation and conse-
quences of autophagy under the condition of low oxygen.
In the context of cancer, activation of autophagy by
hypoxia impacts tumorigenesis, cancer cell viability, and
likely antitumor immunity. Despite the evidence that au-
tophagy functions as a tumor suppressor in hypoxic tissues
[14], the role of autophagy in maintaining the integrity
of established tumors is controversial. One model suggests
that cancer cells rely on autophagy as an adaptive survival
mechanism to oﬀset stressors in the tumor microenviron-
ment [15, 16]. An alternative model proposes that prolonged
autophagy leads to death by apoptosis [17, 18] or initiates a
form of nonapoptotic-programmed cell death, called “type
II” or “autophagic” cell death [19]. The latter form of cell
death is poorly deﬁned mechanistically, and its existence
and deﬁnition have been contested in the literature as it is
unclear whether cells that die in this manner are doing so
by autophagy or simply with features of autophagy [20]. The
role of autophagy in cancer pathology reaches an additional
level of complexity when tumor-inﬁltrating immune cells
are considered. Immune cells traﬃc to tumors where they
are known to recognize and kill neoplastic tissues [21–23].
Given that immune cells in the tumor microenvironment
are also exposed to low oxygen, it is likely that they too
become autophagic. Whether the activation of autophagy
helpsorhindersimmunecellfunctioniscurrentlyunknown.
Therefore, understanding the physiological consequences of
autophagy in diﬀerent cell types in the tumor microenvi-
ronment is critical when considering therapies that target
autophagy.
2. Hypoxia-InducedAutophagy inTumor Cells
2.1.ConﬂictingRolesofHypoxia-InducedAutophagyinTumor
Cells. T h er o l eo fa u t o p h a g yi nh y p o x i ct u m o r si sc o n t r o -
versial given opposing studies that show a correlation of
autophagy with enhanced [8, 24, 25] or decreased tumor cell
survival [14, 26]. Some of these discrepancies may in part
be due to cell type and/or the activating autophagy signal.
Along these lines, hypoxia-induced autophagy has been
demonstrated to promote tumor survival by several mecha-
nisms, including the removal of damaged mitochondria that
produce cytotoxic reactive oxygen species (ROS) [24, 27]
and the degradation of harmful protein aggregates [28, 29].
In addition, autophagy is believed to sustain the energetic
needs of the cell during hypoxia and nutrient withdrawal
by liberating metabolites that can be oxidized to generate
ATP. One way that cells sense and adapt to their ener-
getic requirements is through the energy sensor adenosine
monophosphate-activated protein kinase (AMPK). As the
intracellular ratio of AMP to ATP increases, AMPK activity
promotes autophagy induction serving as a means to prevent
prolonged energy crisis and eventual cell death (Figure 1).
By contrast, hypoxia-induced autophagy has also been
demonstrated to suppress tumor cell growth and survival
[14]. This suppression likely results from a combination of
prolonged self-eating, the activation of cell death associated
withfeaturesofautophagy,andtheinductionofapoptosisby
autophagy-relatedproteins[18,30]. Knowing when and how
autophagyorchestratescancercellsurvivalwhenconsidering
the complex hypoxic milieu in the tumor microenvironment
is therefore essential if appropriately tailored therapies are to
be employed with the goal of crippling tumor cell survival.
2.1.1. Autophagy as a Survival Pathway for Tumor Cells under
Hypoxia. Although autophagy can have negative implica-
tions on tumor growth, it appears that the primary function
of autophagy is to help cancer cells cope with environmental
stress. During hypoxia, autophagy has been demonstrated to
be essential for the survival of various cell types including
human colon and prostate carcinoma cell lines [8]. Elucida-
tion of how autophagy was induced in these cells revealed
that autophagy activation was dependent on the HIF-1-
BNIP3/BNIP3L-Beclin1 interacting axis (Figure 1). HIF-
1α target genes include the autophagy regulatory proteins
BNIP3 (Bcl-2/adenovirus E1B 19-kDa interacting protein 3)
and BNIP3L (BNIP3-like protein). Upregulation of BNIP3
and BNIP3L during hypoxia has been shown to induce the
selective degradation of mitochondria by autophagy (so-
c a l l e dm i t o p h a g y ) ,ap r o c e s st h a tp r o m o t e sc e l ls u r v i v a lb y
reducing the generation of DNA damaging ROS by dysfunc-
tional mitochondria [27]. Mitophagy appears to be impor-
tant for promoting survival during hypoxia in hepatocellular
tumor spheroids which have a natural hypoxic gradient [24].
Here, HIF-1α-induced BNIP3 expression presumably led to
enhanced mitophagy, and when autophagy was inhibited
chemically, increased tumor cell death occurred. Another
report has shown that a BNIP3/BNIP3L-independent form
of HIF-1α-induced autophagy can initiate bulk degradation,
but not mitophagy, under hypoxia in concert with platelet-
derived growth factor receptor family signalling. This latter
form of hypoxia-induced autophagy was also important for
tumor cell survival under hypoxia [31].
Previously, it was shown that p53-deﬁcient tumor cells
adapt to and survive in hypoxic environments superior to
p53-competent tumor cells [32] .Am o r er e c e n ts t u d ys h o w s
that the resistance of these tumor cells to hypoxia may be
in part due to autophagy that is activated by the absence
of p53. Tasdemir et al. were the ﬁrst to report that the
absence of p53 resulted in induction of autophagy via AMPK
in a variety of cell lines. Furthermore, this induction is
speciﬁcally dependent on the absence of cytoplasmic p53
which is canonically responsible for inhibiting autophagy
[25]. When p53-deﬁcient cells were subjected to metabolic
stress (nutrient deprivation and hypoxia), these cells had
a survival advantage over their wild-type counter parts,
but this advantage was abolished if autophagy was inhib-
ited. Interestingly, addition of the mitochondrial substrate
methyl-pyruvate only partially rescued the wild-type cells
subjected to metabolic stress, indicating that autophagy
contributes to prosurvival functions beyond immediate
nutrient mobilization.
During hypoxia, the unfolded protein response (UPR)
is initiated because oxygen is required for the formation
of disulﬁde bonds and the maturation of proteins destined
to be secreted or incorporated into the plasma membrane
[33]( Figure 1). Autophagy can also promote tumor survivalInternational Journal of Cell Biology 3
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Figure 1: Pathways of autophagy induction by hypoxia. During hypoxia, autophagy is activated by sensors that detect low oxygen, unfolded
proteins,andenergydepletion. Low O2: intheabsenceofoxygen,thealphasubunitofthetranscriptionfactorHIF-1isstabilizedresultingin
theexpressionoftheregulatoryproteinsBNIP3andBNIP3L.BNIP3andBNIP3LinteractwithBcl-2andBcl-xLproteinsthatinhibitBeclin1,
a key regulator of autophagy induction. The resulting liberation of Beclin1 leads to the activation of autophagy [8]. (BNIP3L and Bcl-xL
are not shown in the ﬁgure). Unfolded Protein Response: autophagy may be induced during hypoxia as a result of signals generated by the
unfolded protein response in the endoplasmic reticulum. PERK detects unfolded proteins and induces ATF4 to upregulate the expression of
the essential autophagy genes LC3 and ATG5 [28, 29, 33]. LC3 I is processed to its active form, LC3 II, and traﬃcked with the ATG5-ATG12-
ATG16 complex to the elongating autophagosome. Energy Depletion: increases in the intracellular ratio of AMP to ATP during hypoxia
activates AMPK, an energy sensing switch that activates autophagy both directly and indirectly by inhibiting mTOR [14, 101].
during hypoxia by degrading misfolded protein aggregates
that accumulate in the endoplasmic reticulum. In breast
cancer cells, UPR-dependent upregulation of the activating
transcription factor 4 (ATF4) has been shown to induce
cytoprotective autophagy in hypoxic cells [28]. Here, inhi-
bition of autophagy led to increased apoptosis and decreased
viability, indicating that autophagy plays a role in preventing
cell death. UPR signalling has been shown to be required for
sustained autophagy under hypoxia in colorectal carcinoma
and glioma cells which were not able to maintain the LC3
levelsrequiredforautophagyunderprolongedhypoxiawhen
the ATF4-activating protein, PKR-Like ER Kinase (PERK)
(Figure 1), was disrupted [29].
Despite a diverse set of signals which can activate
autophagy, the acute responses to cellular stress primarily
serve to maintain bioenergetic integrity and survival. This
is supported by reports which have demonstrated that
autophagyfreesupnutrientsthatareutilizedtogenerateATP4 International Journal of Cell Biology
and support cell survival [6, 7, 25, 34–36]. However, little
is known about the source and destination of metabolites
that are liberated by autophagic degradation during hypoxia.
It is possible that metabolites are either oxidized in the
mitochondria, or instead held on reserve to be utilized by
oxidative phosphorylation once normoxic conditions are
restored. These are not mutually exclusive possibilities and
could explain how tumor cells evade treatment-induced
apoptosis and subsequently might contribute to tumor
recurrence [29, 37–39].
Clinical evidence also suggests that tumors utilize
autophagy to survive and proliferate during hypoxia. When
assessed alone, high Beclin 1 expression in advanced human
nasopharyngeal carcinoma samples correlated with poor
patient survival [40]. This trend was also found when
assessing Beclin 1 expression in combination with HIF-1α,
indicating that hypoxia-induced activation of Beclin 1 and
autophagy may drive carcinoma cells to survive treatment
and potentially lead to reoccurrence. Similar results have
been reported from a study investigating tissue samples from
colorectal adenocarcinoma [41]. In this study, patients with
either extensive increased or decreased expression of Beclin
1 had poorer survival than patients with normal levels of
Beclin 1 expression. The authors speculated that tumors
with low expression of Beclin 1 had an advantage because
decreased Beclin 1 reduced interactions with anti-apoptotic
proteins, whereas tumors with high expression of Beclin
1 activated autophagy, in turn allowing tumor cells to
overcome conditions that would otherwise result in cell
death. It was also found that extensive overexpression of
Beclin 1 was correlated with markers of both the presence
of hypoxia and cellular adaptation to hypoxia, providing
further evidence supporting the favourable role of hypoxia-
induced autophagy in tumor cell survival.
2.1.2. Autophagy as a Negative Regulator of Tumor Survival
and Growth. A ss o m ec e l l sh a v eb e e no b s e r v e dt od i ew i t h
structural features of autophagy in the absence of apoptotic
markers, some researchers have proposed that cells can die
by autophagy, a term known as autophagic cell death [19].
However, considering that autophagy is primarily a cell sur-
vival process, it is likely that in the majority of such cases, the
cells are actually using autophagy as a last attempt to survive,
as opposed to actually dying by autophagy [20]. Despite this,
the idea that cancer cells can undergo death by excessive
autophagy has attracted attention from various groups
looking to exploit autophagy as a way to kill tumors [14,
26]. Hypoxia-induced autophagy has been demonstrated to
reduce survival in several cell types including glioma, breast
cancer, and human embryonic kidney cells independent
of apoptosis [26]. In all of these cell types, autophagy-
d e p e n d e n tc e l ld e a t hw a so b s e r v e df o l l o w i n gp r o l o n g e d
exposure to hypoxia. This decrease in tumor cell survival was
abrogatedwhenautophagywasinhibited,suggestingthatcell
death associated with autophagy may have been responsible
for the reduction in cellular viability. However, further
investigation into the mechanism of autophagy induction
in this study revealed that it involved BNIP3. Given that
BNIP3-induced autophagy is associated with the activation
of mitophagy, a process that is generally cytoprotective
during hypoxia [27], it appears that the duration of hypoxia
treatment may have caused cells to eat themselves to death
or deplete mitochondria to levels insuﬃcient for survival.
Despite the fact that the cancer cells mentioned above ini-
tially survived by autophagy [26], this process is self-limiting
andcouldbeviewedasafailedattempttosurviveratherthan
a classical cell death pathway when cells succumb to death.
An alternative explanation for why autophagy negatively
impactscellsurvivalduringhypoxiaisthatspeciﬁcsignalling
events may occur in certain cell types, triggering cell
death associated with autophagy. Experimental evidence in
support of this model demonstrated that mouse embryo
ﬁbroblasts (MEFs) cultured under hypoxia and nutrient
replete conditions activate autophagy through AMPK sig-
nalling, independent of HIF-1α, resulting in cell death
[14]. Interestingly, if ATG5 was knocked out, the cells had
increased viability under hypoxia. In this study, autophagy
competent MEFs were less glycolytic than ATG5 knockout
MEFs,indicatingthattheswitchtoglycolysisisimportantfor
hypoxic cells to survive. One possibility is that metabolites
liberated by autophagy in these cells are fed into oxidative
phosphorylation, hindering the switch to glycolysis and thus
negatively aﬀecting the viability of these cells under hypoxia.
This hypothesis is supported by the fact that mitochondria
are not speciﬁcally degraded without HIF-1α activation
[27]. Therefore, aberrant oxidation of autophagy-derived
nutrients in the mitochondria may contribute to ROS-
mediated cell death in these cells.
In addition to slowing tumor growth by triggering
excessive self-eating and death associated with autophagy,
hypoxia-induced autophagy can also activate apoptotic cell
death. The positive eﬀect of ATG5 deletion in the previous
example [14] might also be explained by a role of ATG5
to drive apoptosis. One study demonstrated that ATG5
cleavage and translocation into the mitochondria triggers
cytochrome C release and caspase cleavage [18, 42]. The
cross-talk between autophagy and apoptosis during hypoxia
is further highlighted in models of transformed rat epithelia,
where overexpression of the essential autophagy gene, Beclin
1, results in caspase dependent cell death [17]. It is possible
thatBeclin1exertsitsprodeathfunctionthroughitscaspase-
mediated cleavage [30, 43] or by binding to Bcl-2 or Bcl-
xL, sequestering these proteins and preventing them from
exerting their prosurvival functions [44]( Figure 1).
2.1.3. Autophagy as a Method of Treatment Resistance under
Hypoxia. Hypoxic tumor cells present a particular chal-
lenge when treating cancer patients because these cells are
often more resistant to many forms of anticancer therapy
than normoxic cells [45]. The involvement of autophagy
in mediating this resistance was shown by inhibiting or
knocking down autophagy in tumor cells treated with the
chemotherapy drug cisplatin under hypoxia. Abrogation of
autophagy reduced tumor cell viability to levels similar to
those observed when cells were treated with cisplatin under
normoxia [46]. Interestingly, the synergistic eﬀect between
chemotherapy treatment and autophagy inhibition is not
always observed under normoxia, but rather only underInternational Journal of Cell Biology 5
hypoxia.Anexampleofadrugforwhichthishasbeenshown
is N-(4-hydroxyphenyl)retinamide [47]. This phenomenon
brings up an important consideration when testing for
cancer treatment sensitivity by autophagy inhibition. In light
of the fact that solid tumors will experience some degree
of hypoxia and these cells are often the most resistant to
treatment, autophagy inhibition and cancer treatment com-
bination experiments should be performed in vitro not only
under normoxic conditions, but also under low oxygen. In
addition, scenarios of cycling and chronic hypoxia which are
present in vivo may also need to be taken into consideration.
Not all anticancer agents display reduced cytotoxicity
towards hypoxic cells. In fact, some drugs, such as Borte-
zomib, have been demonstrated to have increased eﬃcacy
under hypoxia [48]. Bortezomib is a proteasome inhibitor
that induces autophagy by stimulating the unfolded protein
response. Inhibition of autophagy concurrently with Borte-
zomib treatment under hypoxia resulted in greater apoptosis
of cervical carcinoma cells [48]. Coupling a proteasome
inhibitor with an autophagy inhibitor when treating hypoxic
tumors is very attractive given that hypoxia results in
misfolded proteins and inhibiting both the proteasome and
autophagy blocks the cell’s two key methods for disposing of
such proteins.
Another diﬃculty with the treatment of hypoxic tumors
is their increased resistance to radiation therapy. Interest-
ingly, this resistance can be circumvented by inhibiting
autophagy as has been shown in mouse xenograft models
of colorectal carcinoma and glioma [29]. This is an exciting
result since hypoxic cells are notorious for being resistant to
radiation. A simple method for sensitizing such cells would
be of signiﬁcant clinical beneﬁt.
Considering the results discussed above, cancer cells
predominantlyuseautophagyasasurvivalmechanismunder
hypoxia. Therefore, inhibiting autophagy in hypoxic cancer
cells may be exploited to increase treatment eﬃcacy. How-
ever, accumulating evidence suggests that autophagy also
plays an important role in mediating immune cell survival,
development,andfunction[49,50].Giventhatarobustanti-
tumor immune response is associated with increased patient
survival in several cancer types, further consideration must
be given to the immunological consequence of autophagy
inhibition in the tumor microenvironment.
3.Autophagy inImmuneCellsina Hypoxic
Tumor Environment
3.1. Immunosurveillance of Tumor Growth by Innate and
Adaptive Immune Cells. The tumor microenvironment is
inhospitable not only for tumor cells but also immune cells
thattraﬃctothetumorbed.Thishostilityiscompoundedby
immunosuppressive molecules secreted from the tumor cells
into the environment, including nitric oxide, adenosine, and
suppressive cytokines [51–53]. In spite of these hurdles, mul-
tiple cell types within the innate and adaptive immune sys-
tem are capable of recognizing and eliminating tumor cells.
Professional antigen presenting cells (APCs) such as
macrophages, B cells, and dendritic cells (DCs) display
peptides phagocytosed in the tumor environment on major
histocompatibility complex (MHC) molecules for recogni-
tion by T cells. Phagocytosed tumor antigens are either
presented on MHC class II molecules which activate helper
CD4+ T cells, or the antigen is cross-presented onto MHC
class I molecules to activate antitumor cytotoxic CD8+ T
cells [54]. Overall, the innate immune system is linked to
the adaptive immune system through APC presentation of
tumor-speciﬁc or associated antigens in combination with
costimulatory signals, allowing for antitumor activity.
Because the immune system must directly interact with
tumors to facilitate cell death, its components experience
hypoxia in the tumor microenvironment. Immune cells
need to adjust their metabolic dependency once they have
reached the tumor and may also use autophagy to enhance
their survival. In the following section we review the ways
autophagy might inﬂuence immune responses under low
oxygen conditions.
3.2. The Role of Autophagy in Antitumor Innate Immune
Cells Inﬁltrating into Hypoxic Tumor Sites. Tumors are often
associated with chronic inﬂammation, a host response to
deal with damaged tissues or infection [55]. Neutrophils are
the ﬁrst innate cell type to migrate to the inﬂammatory site
wheretheypromote inﬂammation andactivatemacrophages
and DCs [56]. Unlike other immune cell types, neutrophils
are programmed with a high glycolytic rate making them
especially resistant to hypoxia, a property relevant for their
performance in hypoxic tumors [57]. Autophagy has been
shown to mediate programmed necrotic cell death of neu-
trophils under inﬂammation, and this late stage induction of
cell death might serve as a mechanism to limit inﬂammation
[58]. In the tumor environment this mechanism might
impact one of the earliest antitumor immune responses by
impairing neutrophil survival.
In contrast to neutrophils, APCs must metabolically
adapt to low oxygen through stabilization of HIF-1α to
induce increased expression of glucose transporters and
glycolytic enzymes as well as limiting oxygen consuming
oxidative phosphorylation [5]. As a consequence of hypoxia,
APCs, such as macrophages and DCs, have decreased phago-
cytosis, reduced migratory capacity, and increased produc-
tion of proangiogenic and proinﬂammatory cytokines such
as vascular endothelial growth factor, tumor necrosis factor
alpha, interleukin-1 (IL-1), and IL-12 [59–61]. For example,
a recent study showed that DCs cultured under low oxygen
resulted in skewing from a type 1 helper CD4+ T cell pheno-
typetoatype2helperCD4+Tcellphenotype,whichismore
immunosuppressive and less beneﬁcial for tumor killing
[62]. While hypoxia is involved in dampening APC activity,
autophagy may contribute to survival of APCs under these
conditions. Importantly, Naldini et al. found that culturing
DCs under low oxygen resulted in the stabilization of HIF-
1α which initiated BNIP3 expression and promoted survival
of mature DCs, possibly due to induction of autophagy [63].
In APCs inﬁltrating a tumor, hypoxia-induced autophagy
can also occur via diﬀerent signalling mechanisms such
as toll-like receptor (TLR) signalling [64, 65]. A proposed
mechanism of how hypoxia-induced autophagy inﬂuences
APC function is shown in Figure 2.6 International Journal of Cell Biology
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Figure 2: Proposed roles for hypoxia-induced autophagy in APCs. During low oxygen HIF-1α initiates TLR4 transcription [102]. TLR4
can then be engaged by HMGB1 (high-mobility group box-1 protein), a danger-associated molecular pattern molecule released from
dying tumor cells after chemotherapy or radiation resulting in activation of the APC [103]. The engagement of TLR4 results in signalling
throughadaptormoleculesMyD88(myeloiddiﬀerentiationprimaryresponsegene88)andTRIF(TIR-domain-containingadapter-inducing
interferon-β) which both inhibit the interaction of Bcl-2 with Beclin 1 to induce autophagy [64, 65]. Autophagy can then aid in processes
such as improved phagosomal degradation and MHC presentation of tumor antigens for activation of the immune response [66, 67].
I ns u m m a r y ,a u t o p h a g yp l a y sac e l ld e a t hr o l ei nn e u -
trophils which may serve as an anti-inﬂammatory mecha-
nism to regulate neutrophils in a hypoxic tumor. In contrast,
autophagy in tumor-inﬁltrating APCs is involved in survival,
likely by liberation of nutrients required to support the
energy demands of an activated cell and is important for
the cell’s antigen presentation capabilities [66, 67]. The
induction of autophagy under hypoxia may serve to improve
metabolism under these conditions and allow for mainte-
nance of proper antitumor immune function. Considering
the fact that autophagy was shown to be important for the
processofantigenpresentation,itmaybeinvolvedinpositive
eﬀects of APC presence within tumors such as activation of
T cells through improved MHC expression.
3.3. Autophagy as a Modulator for T Cell-Mediated Immunity
under Hypoxic Conditions. Many immune therapies modu-
late T cell eﬀector function as a means to increase antitumor
immunity [22, 68–71] .Tc e l l sa r ea b l et oi d e n t i f yt u m o r
cells via tumor associated antigens, which are derived from
proteins either mutated or not normally exposed to the
immune system. Antigen recognition and stimulation of T
cells in the tumor environment occurs in the presence of
immunosuppressive factors that impact the eﬃcacy of the
T cell-mediated antitumor response. In the next section,
we describe how hypoxia aﬀects the fate of T cells in two
ways. First, the immunosuppressive role of hypoxia will be
considered. Second, hypoxia will be examined as a potent
activator of autophagy and modulator of metabolism, which
helps intratumoral T cells exposed to the hypoxic tumor
milieu to survive.
3.3.1. Signalling Events and Metabolism in Activated T Cells.
Newly activated T cells metabolically adapt to facilitate
growth and proliferation. This process is modulated by
several signalling pathways, including AMPK, HIF-1α,a n d
mTOR (mammalian target of rapamycin) (Figure 3)[ 72–
74]. Within one minute after engagement of the T cell
receptor, AMPK becomes fully activated due to calcium
inﬂux into the cytoplasm [72]. AMPK upregulates ATPInternational Journal of Cell Biology 7
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Figure 3: Signalling events and metabolic consequences in T cells. In the absence of activation signals, na¨ ıve cells utilize oxidative
phosphorylation (OxPhos) as the main source of cellular bioenergetics. This is in part supported by basal levels of autophagy necessary
to maintain energy and protein turnover homeostasis. Within the ﬁrst hour of T cell activation, AMPK activity predominates leading to
suppression of mTOR which results in upregulation of glycolysis, OxPhos as well as autophagy. Together these pathways provide the initial
wave of bioenergetics to support growth. During the transition to the proliferative state, AMPK signalling declines and mTOR activity
increases which in turn enforces nutrient uptake and glycolysis. As eﬀector T cells enter the hypoxic tumor microenvironment, HIF-1α
accumulation reduces OxPhos and further augments glucose-dependent metabolism. At later stages of prolonged hypoxia, exhaustion of
glucose activates AMPK leading to mTOR suppression and the activation of autophagy-dependent survival and eﬀector T cell antitumor
function.
producing processes including fatty acid oxidation and
glycolysis supported by elevated glucose inﬂux, while
also inhibiting ATP-consuming processes including protein,
glycogen,andfattyacidsynthesis.Moreover,AMPKactivates
autophagy by suppressing mTOR, the master regulator of
protein synthesis, growth and proliferation, and suppressor
of autophagy [74, 75]. This has the dual beneﬁt of supplying
cells with biosynthetic precursors via glycolysis and maximal
energy production derived from oxidation of carbon sub-
strates in the mitochondria. One assumption is that early
activation of AMPK is crucial for increasing the cellular pool
of ATP as a means to prepare T cells for the upcoming bioen-
ergetic and biosynthetic demands of rapid proliferation.
Following the ﬁrst hour after T cell receptor engagement,
AMPK activity subsides, resulting in the abrogation of the
AMPK-mediatedsuppressionofmTOR[76].Tosustainhigh
levelsofgrowth,Tcellssecreteproliferativecytokines likeIL-
2thatactinaparacrinemannertoactivatemTORsignalling.
This second wave of signal transduction reinforces the cells
to sustain a high metabolic state of upregulated glycolysis
[77]. The dependency of activated T cells on glycolysis allows
for energy production even in regions of low oxygen levels
such as in inﬂamed tissues or hypoxic tumors. Additionally,
glycolytic intermediates are the predominant sources of
metabolites used in nucleic acid and lipid biosynthesis dur-
ing periods of rapid T cell growth and proliferation [78, 79].
3.3.2. Impact of Hypoxia on T Lymphocytes. Upon entry of
T cells into sites of hypoxia, HIF-1α accumulation enables
the cells to survive within regions of low oxygen, but also
suppresses T cell function to avoid an excessive immune
response that potentially damages healthy tissue. Unfortu-
nately, this suppression of T cell function may also occur in
a hypoxic tumor environment, leading to a down regulated
antitumor immune response. Evidence for the suppressive
activity of hypoxia on T cells was ﬁrst described in mouse
lymphoid cells. This initial study showed that incubation
of na¨ ıve T cells under hypoxia prior to their activation
led to the reduction of the proliferative cytokine IL-2
[80]. Subsequent investigations of mouse T cells in which
HIF-1α was genetically knocked down revealed that this
cytokine suppression was dependent on HIF-1α expression
[81]. Importantly, activation of T cells under low oxygen
conditionswasalsoshowntoimpairTcellproliferation[81].
These functional T cell defects can partly be explained by
interference of HIF-1α with calcium signalling, one of the
early events initiated by T cell receptor engagement [82, 83].
In addition to the direct suppression of T cell activity,
HIF-1α was also demonstrated to indirectly modulate T cell
mediated killing by inﬂuencing the diﬀerentiation of CD4+
T cells [84, 85]. The four functional CD4+ subsets Th1,
Th2, Th17, and T regulatory cells have diﬀerent levels of
glycolytic activity. HIF-1α controls diﬀerentiation into these
eﬀector subsets by modulating their metabolic signatures
[85]. Moreover, lymphoid cells were shown to upregulate
FoxP3 when cultured under hypoxia as a result of HIF-1α
stabilization [84]. FoxP3 is the transcription factor driving
CD4+ T cell diﬀerentiation towards T regulatory cells, which
is known to attenuate T cell-mediated immune responses
[86]. Interestingly, this transcription factor has also been
identiﬁed as an important immunosuppressive factor espe-
cially in antitumor immunity [87]. The observation that T
regulatory cells are even more eﬃcient in their suppressive
activity under low oxygen conditions once more underscores
the immunosuppressive nature of hypoxia [84].
3.3.3. Survival Mechanisms of T Cells under Hypoxia. In
addition to the various roles of HIF-1α on the suppression8 International Journal of Cell Biology
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Figure 4: Proposed roles of autophagy under hypoxia in tumor immunology. Autophagy induction may improve phagocytosis maturation
by enhancing degradation of tumor cells by innate immune cells. Autophagy aids in both the cross presentation of exogenous antigens
on MHC class I and presentation of endogenous antigens on MHC class II. In T lymphocytes, autophagy enables activation by providing
available nutrients from the degradation of macromolecules. It also enables cytotoxic cytokine secretion which enhances tumor cell killing.
All cell types, including both immune cells and tumor cells, may utilize autophagy to enhance survival under hypoxic and nutrient deprived
conditions.
of T cell-mediated immune responses, it has also been
shown to act as a cell survival factor in T cells. For example,
stabilization of HIF-1α represses activation-induced cell
death (AICD), a process that is mediated by the Fas-Fas
ligand death receptor pathway [88]. This ﬁnding is especially
important for antitumor T cells, because one mechanism of
the tumor’s immune evasion is an elevated expression of Fas
ligand for the induction of tumor-mediated AICD [89].
As mentioned in the sections above, HIF-1α expression
induces tumor cell autophagy (Figure 1). However, the role
of HIF-1α-dependent activation of autophagy in lymphoid
cells has not yet been reported. In T cells, autophagy
is activated upon T cell receptor engagement in both
CD4+ and CD8+ subtypes [90–92]. The knockdown of the
essential autophagy-related genes ATG5 or ATG7 during
T cell receptor stimulation leads to a signiﬁcant decrease
in cellular proliferation demonstrating the importance of
autophagy during T cell activation [91, 92]. At later time
points after activation, autophagy-deﬁcient T cells undergo
apoptosis at an unusually high degree, which may be
due to a defect in the initial signalling events of T cell
activation. Support for this idea comes from the ﬁnding
that T cell stimulation by phorbol myristate acetate (PMA)
and Ionomycin, which bypasses T cell receptor signalling,
results in almost normal proliferation rates of autophagy-
incompetent T cells [91]. Interestingly, PMA/Ionomycin
treatment triggers calcium inﬂux into the cytoplasm which,
as previously mentioned, activates AMPK during the initial
phase of T cell activation. However, in which way autophagy
interferes with T cell receptor signalling remains to be fully
determined. Primary investigations of the signalling events
uponTcellreceptorengagementinautophagy-deﬁcientcells
have revealed impaired mTOR and AMPK activity [92].
This goes together with the observation that the increase
in the cellular ATP levels, which is expected upon T cell
activation, could not be detected [92]. The ﬁnding that a
low rate of ATP generation occurs together with decreased
fatty acid usage and impaired AMPK activation strongly
implicates AMPK-induced autophagy as an essential process
for breaking down intracellular lipids for ATP production
during T cell activation [92]. These ﬁndings suggest that the
activation of na¨ ıve T cells may require initial AMPK-induced
autophagy to sustain the ﬁrst wave of energy demands prior
to the upregulation of metabolite transporters and metabolic
enzymes needed for growth and proliferation.
Another functional role of autophagy has been demon-
strated in eﬀector CD4+ T helper 1 cells. These cells were
found to have a profound defect in their ability to secrete
IL-2 when autophagy was blocked during stimulation [92].
Notably, the deﬁciency in autophagy did not interfere with
the process of IL-2 secretion but rather with the synthesis
of IL-2 itself. Interestingly, IL-2 expression was restored
withmethyl-pyruvateaddition,suggestingthatthedecreased
capability of autophagy-deﬁcient T cells to fuel metabolismInternational Journal of Cell Biology 9
doesnotonlyimpairtheirproliferationbutalsoimpairstheir
eﬀector functions.
In recent years, the autophagy suppressor mTOR has
been in the research spotlight because of its cell-intrinsic role
f o rm e m o r yTc e l ld i ﬀerentiation. Inhibition of mTOR by
rapamycin during T cell activation and proliferation results
inanenhancedfrequencyofCD8+memoryTcells[93].This
eﬀect was determined to be mediated by the ability of mTOR
to inﬂuence the transcription factors t-bet and eomesoder-
min, which were shown to be crucial in determining eﬀector
Tc e l lf a t e[ 94]. However, the augmented CD8+ memory
T cell response upon mTOR inhibition was also shown to
be associated with changes in metabolism [95]. Rapamycin-
treated eﬀector T cells gained ATP mainly through oxidative
phosphorylation and exhibited a memory precursor like
phenotype which could allow for long-lasting antitumor
immunity. Thesecellswerealsomoreresistantto growthfac-
tor withdrawal-induced cell death. The ﬁnding that memory
precursor cells were generated by switching their metabolism
tooxidativephosphorylationunderscoresthehypothesisthat
the metabolic characteristics of eﬀector cells are crucial for
the formation of CD8 memory [95]. Although these results
were not discussed in connection with the eﬀect of mTOR
inhibitionontheinductionofautophagy,aroleofautophagy
in the fate decision of memory T cells is a possibility.
4. Conclusion
The tumor microenvironment is complex, comprised of
a variety of factors that can act on all cells including
immune and cancer cells (Figure 4). One of the predominant
factors is hypoxia, which is a known inducer of autophagy.
Though hypoxia-induced autophagy promotes cellular sur-
vivalandfunction,hypoxia-inducedautophagyhasalsobeen
demonstrated to negatively impact the viability of speciﬁc
tumor types. In order to reconcile this disparate observation,
further investigation is required to understand what factors
dictate whether autophagy enhances or suppresses cellular
viability during hypoxia. This is paramount since numerous
drugs that target the hypoxia pathway have been deployed
to treat cancer and their impact on autophagy has not been
examined. For example, agents such as AvastinTM reduce
the formation of new blood vessels in hypoxic tumors
[96], but may indirectly promote tumor cell autophagy
and survival. Moreover, despite the widespread belief that
mTOR controls tumor growth and proliferation, clinical
trials with mTOR inhibitors have been disappointing [97,
98]. It could be argued that the ineﬀectiveness of mTOR
blockage is due to autophagy activation and therefore this
approach should be combined with a suitable inhibitor
of autophagy. This idea is supported by preclinical data
demonstrating the synergistic eﬀect of autophagy-inducing
agents (chemotherapy, radiation) and the use of an inhibitor
of autophagy in cells reliant on this survival pathway. Several
studies in human prostate, colon, breast, and lung cancers
are now underway to examine combined chemotherapy
and autophagy inhibition using the antimalarial hydroxy-
chloroquine (NCT00786682, NCT01206530, NCT01006369,
NCT00765765, NCT00933803 reviewed by [99, 100]).
The key question is whether autophagy inhibition in
the clinical setting will prove to be speciﬁc enough to
selectively kill tumor cells. Since there is mounting evidence
to suggest that autophagy induction enhances immune cell
function, therapeutic strategies targeting this pathway must
takeintoaccountthepotential negativeimpactonantitumor
immunity. Given that the immune system is a powerful foe
to cancer, therapies that do little to dampen the antitumor
immune response, or preferably enhance the response would
beoptimal. Furtherresearchwillbeessentialfordetermining
how best to modulate autophagy in cancer patients with this
goal in mind.
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